title: Daclatasvir (Daklinza) for HCV genotype 3 infection.
abstract: Daclatasvir (Daklinza) plus sofosbuvir (Sovaldi) is the first all-oral, interferon- and ribavirin-free drug regimen for treatment of hepatitis C virus genotype 3 infection. This combination is effective and convenient, but it is very expensive.
mesh_terms: D000818:Animals; D000998:Antiviral Agents / Q000008:administration & dosage*; D002219:Carbamates; D002986:Clinical Trials as Topic / Q000379:methods; D004359:Drug Therapy, Combination; D005838:Genotype; D016174:Hepacivirus / Q000187:drug effects*; D006526:Hepatitis C / Q000175:diagnosis / Q000188:drug therapy*; D006801:Humans; D007093:Imidazoles / Q000008:administration & dosage*; D011759:Pyrrolidines; D000069474:Sofosbuvir / Q000008:administration & dosage*; D014633:Valine / Q000031:analogs & derivatives
chemical_list: D000998:Antiviral Agents; D002219:Carbamates; D007093:Imidazoles; D011759:Pyrrolidines; D014633:Valine; C549273:daclatasvir; D000069474:Sofosbuvir